-
Barrientos L G, O'Keefe B R, Bray M, Sanchez A. Cyanovirin-N binds to the viral surface glycoprotein, gp1, 2 and inhibits infectivity of Ebola virus[J]. Antiviral Res, 2003, 58(1): 47-56. doi: 10.1016/S0166-3542(02)00183-3
-
Bewley C A, Gustafson K R, Boyd M R. Solution structure of cyanovirin-N, a potent HIV-inactivating protein[J]. Nat Struct Bio, 1998, 15(7): 571-578.
-
Bolmstedt A J, O'Keefe B R, Shenoy S R. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner[J]. Mol Pharmacol, 2001, 59(5): 949-954.
-
Boyd M R, Gustafson K R, McMahon J B. Discovery of cyanovirin-N, a novel human immunode-ficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development[J]. Antimicrob Agents Chemother, 1997, 41(7): 1521-1530.
-
Campling B G, Pym J, Galbraith P R. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells[J]. Leuk Res, 1988, 12(10): 823-831. doi: 10.1016/0145-2126(88)90036-7
-
Cunha B A, Eisenstein L E, Dillard T. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy[J]. Heart Lung, 2007, 36(1): 72-78. doi: 10.1016/j.hrtlng.2006.07.005
-
De Clercq E. Antiviral drugs in current clinical use[J]. J Clin Virol, 2004, 30(2): 115-133. doi: 10.1016/j.jcv.2004.02.009
-
Dey B, Lerner D L, Lusso P. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses[J]. Virology, 2000, 74(10): 4562-4569. doi: 10.1128/JVI.74.10.4562-4569.2000
-
Ferrari A, Luppi M, Potenza L. Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature[J]. Leukemia, 2005, 19(11): 2019-2021. doi: 10.1038/sj.leu.2403893
-
Frobert E, Ooka T, Cortay J C. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study[J]. Antimicrob Agents Chemother, 2005, 49(3): 1055-1059. doi: 10.1128/AAC.49.3.1055-1059.2005
-
Frobert E, Ooka T, Cortay J C. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study[J]. Antiviral Res, 2007, 73(2): 147-150. doi: 10.1016/j.antiviral.2006.08.001
-
Gustafson K R, Sowder R C, Henderson L E. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum[J]. Biochem Biophys Res Commun, 1997, 238(1): 223-228. doi: 10.1006/bbrc.1997.7203
-
Han Z, Simpson J T, Fivash M J. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein[J]. Peptides, 2004, 25(4): 551-561. doi: 10.1016/j.peptides.2004.02.018
-
Koharudin L M, Viscomi A R, Jee J G. The evolutionarily conserved family of cyanovirin-N homologs: structures and carbohydrate specificity[J]. Structure, 2008, 16(4): 570-584. doi: 10.1016/j.str.2008.01.015
-
Lv R, Yu H, Liu ZT. Prokaryotic expression of the CV-N gene, purification and renaturation of its recombinant protein[J]. J Med Postgrad, 2007, 20(11): 1139-1142.
-
Mori T, Barrientos L G, Han Z. Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts[J]. Protein Expr Purif, 2002, 26(1): 42-49. doi: 10.1016/S1046-5928(02)00513-2
-
Mori T, Gustafson K R, Pannell L K. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium[J]. Protein Expr Purif, 1998, 12(2): 151-158. doi: 10.1006/prep.1997.0838
-
O'Keefe B R, Shenoy S R, Xie D. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41[J]. Mol Pharmacol, 2000, 58(5): 982-992.
-
O'Keefe B R, Smee D F, Turpin J A. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin[J]. Antimicrob Agent Chemother, 2003, 47(8): 2518-2525. doi: 10.1128/AAC.47.8.2518-2525.2003
-
Russel D B, Tabrizi S N, Russel J M. Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting[J]. J Clin Virol, 2001, 22(3): 305-313. doi: 10.1016/S1386-6532(01)00203-7
-
Severson J L, Tyring S K. Relation between herpes simplex viruses and human immunodeficiency virus infections[J]. Arch Dermatol, 1999, 135(11): 1393-1397.
-
Smee D F, Bailey K W, Wong M H. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N[J]. Antiviral Res, 2008, 80(3): 266-271. doi: 10.1016/j.antiviral.2008.06.003
-
Tiwari V, Shukla S Y, Shukla D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion[J]. Antiviral Res, 2009, 84(1): 67-75. doi: 10.1016/j.antiviral.2009.07.014
-
Waggoner-Fountain L A, Grossman L B. Herpes simplex virus[J]. Pediatr Rev, 2004, 25(3): 86-93. doi: 10.1542/pir.25-3-86
-
Wang K, Mahalingam G, Hoover S E. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia[J]. J Virol, 2007, 81(13): 6817-6826. doi: 10.1128/JVI.00166-07
-
Whitely R J, Roizman B. Herpes simplex virus infections[J]. Lancet, 2001, 357(): 1513-1538. doi: 10.1016/S0140-6736(00)04638-9
-
Yi M, Wei K, Wang X F. Primary studies on the establishment of herpes simplex encephalitis in murine model[J]. Pediatr Emerg Med, 2000, 7(2): 26-27.